Trial · NCT01275300
Biosynthesis of PGD2 in Vivo
NCT01275300, Not applicable, Completed, University of Pennsylvania; results first posted 2020-07-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Biosynthesis of PGD2 in Vivo. Trials, record NCT01275300. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01275300
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Biosynthesis of PGD2 in Vivo
- NCT number
- NCT01275300
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 9 participants, actual
- Lead sponsor
- University of Pennsylvania
- Conditions
- Hyperlipidemia
- Interventions
- Aspirin, Placebo, Niacin
- First posted
- 2011-01-12
- Last updated
- 2026-02-09
- Results first posted
- 2020-07-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo | -2-0, 0-2, 2-4, 4-6, 6-12 and 12-24 hours pre or post niacin | Percentage change of area under the urinary prostaglandins concentration versus time curve (AUC) in response to niacin with or without pretreatment of aspirin was studied. This outcome measures whether aspirin instead of placebo will impact the subjects' response to niacin. The area was normalized by percentile. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo | -2-0, 0-2, 2-4, 4-6, 6-12 and 12-24 hours pre or post niacin | Percentage change of area under curve | MEAN |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo | Placebo | 95 | 95% Confidence Interval 93 to 97 | Percentage change of area under curve | |
| Percentage Change of Area Under Curve for the Urinary Prostaglandins Concentration Versus Time Curve (AUC) in Response to Aspirin or Placebo | Aspirin | 43 | 95% Confidence Interval 38 to 48 | Percentage change of area under curve |
Source ClinicalTrials.gov
Participant flow30
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| 1st Intervention (5 Days) | STARTED | Placebo+Niacin First, Then Aspirin+Niacin | 5 | |
| 1st Intervention (5 Days) | STARTED | Aspirin+Niacin First, Then Placebo+Niacin | 4 | |
| 1st Intervention (5 Days) | COMPLETED | Placebo+Niacin First, Then Aspirin+Niacin | 5 | |
| 1st Intervention (5 Days) | COMPLETED | Aspirin+Niacin First, Then Placebo+Niacin | 4 | |
| 1st Intervention (5 Days) | NOT COMPLETED | Placebo+Niacin First, Then Aspirin+Niacin | 0 | |
| 1st Intervention (5 Days) | NOT COMPLETED | Aspirin+Niacin First, Then Placebo+Niacin | 0 | |
| Washout (14 Days) | STARTED | Placebo+Niacin First, Then Aspirin+Niacin | 5 | |
| Washout (14 Days) | STARTED | Aspirin+Niacin First, Then Placebo+Niacin | 4 | |
| Washout (14 Days) | COMPLETED | Placebo+Niacin First, Then Aspirin+Niacin | 5 | |
| Washout (14 Days) | COMPLETED | Aspirin+Niacin First, Then Placebo+Niacin | 4 |
1 to 10 of 30Source ClinicalTrials.gov
See all 30 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | P1: Placebo/Aspirin Followed by Niacin | 0 | 9 |
| Total, all-cause mortality | P2: Aspirin and Niacin | 0 | 9 |
| Total, other adverse events | P1: Placebo/Aspirin Followed by Niacin | 0 | 9 |
| Total, other adverse events | P2: Aspirin and Niacin | 0 | 9 |
| Total, serious adverse events | P1: Placebo/Aspirin Followed by Niacin | 0 | 9 |
| Total, serious adverse events | P2: Aspirin and Niacin | 0 | 9 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 22406532 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| P1: Placebo/Aspirin Followed by Niacin vs P2: Aspirin and Niacin: deaths from any cause | Trial comparisons |
| P1: Placebo/Aspirin Followed by Niacin vs P2: Aspirin and Niacin: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01275300
GET https://conductscience.org/api/trials/v1/NCT01275300/flow?page=2